ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 350

Atypical Femur Fracture in Rheumatoid Arthritis Patients Treated with Bisphosphonates: A Nested Case-Control Study

JungHee Koh1, Ji Hyeon Ju2, Min Kyung Chung3, Ji Hun Kim3, Seung Min Jung4, Ji Yeon Lee2, Jennifer Lee3, Seung-Ki Kwok5 and Sung-Hwan Park3, 1Seochogu, Banpodaero, 222, Division of Rheumatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, 2Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 3Division of Rheumatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, 4Division of Rheumatology, Department of Internal Medicine, school of medicine, The catholic university of Korea, Seoul, South Korea, 5[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Bisphosphonates, Femur Fractures, radiography and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:
Patients with rheumatoid arthritis (RA)
are diagnosed with osteoporosis earlier than and those without RA, and are
therefore exposed to Bisphosphonates (BPs) for longer. The long-term BPs treatment
is one of the suggested predisposing factors for atypical
femur fracture (AFF).
Thus the aims of the present study were to examine
the incidence and clinical characteristics of BPs-associated AFF and to identify
predictors of AFF in patients with RA.

Methods: An age-
and sex- matched nested case-control study was conducted based on 7 years of
data collected at Seoul St. Mary’s Hospital, a
tertiary rheumatology center. All patients treated
with BPs met the 2010 RA
classification criteria. AFFs
were defined as atraumatic or low-trauma fractures of the subtrochanteric or
femoral shaft (Figure 1A). Ten cases of AFF were
identified by reviewing surgical procedures and
radiographs of the low extremities. The study included
40 age- and sex-matched controls with RA but without AFF. The
femorotibial angle (FTA) was measured on radiographs taken with the patient
standing to examine alignment of the lower limb under weight-bearing conditions
(Figure 1B).

Results: All patients
with AFF were female (age, 66.3±8.7 years) and 90% of cases involved fracture
of the proximal femur. The mean length of BPs exposure for patients with AFF was
7.4±3.2 years. Patients with AFF had longer exposure to BPs and a smaller FTA (P
< 0.001 and 0.010, respectively, Table 1). There were no differences in
RA duration, medications taken during the previous 6 months, and bone mineral
density in the femur and lumbar spine between patients with and without AFF.
Multivariate logistic analyses identified BPs exposure (odds ratio [OR], 2.145;
95% confidence interval [CI], 1.175–4.283) and interestingly a FTA < 175°Æ
(OR, 114.796; 95% CI, 2.263–5821.991) as being associated with an increased
risk of AFF.

Conclusion: RA
patients with a valgus deformity and receiving long-term BPs are at higher risk
of AFF than matched RA control subjects. These patients should be carefully
followed up with X-rays or dual energy bone densiometry.

Figure
1
(A) Anteroposterior radiopraph
shows right atypical subtrochanteric fracture and a cortical thickness at the
left lateral cortex (arrow) (B) Measurement of femorotibial angle (FTA) on a
radiograph. The FTA is the lateral angle between the axis of the femoral shaft
and that of the tibial shaft

Table
1. Clinical characteristics of rheumatoid arthritis
patients ever exposed bisphosphonates according to experience atypical femur
fracture

 

Non-fracture

Atypical fracture

P-value

BMI, kg/m2

22.2±2.7

23.7±1.9

0.090

RA duration, yrs

12.7±10.1

10.2±5.0

0.454

Total bisphosphonates exposure*, yrs

3.8±2.3

7.4±3.2

<0.001

Drug holiday, n (%)

18 (45)

0

0.009

Cumulative oral prednisolone dose, g

5.2±4.3

8.7±12.7

0.417

*
In case of AFFs, total BPs exposure was computed just before fracture.

 


Disclosure: J. Koh, None; J. H. Ju, None; M. K. Chung, None; J. H. Kim, None; S. M. Jung, None; J. Y. Lee, None; J. Lee, None; S. K. Kwok, None; S. H. Park, None.

To cite this abstract in AMA style:

Koh J, Ju JH, Chung MK, Kim JH, Jung SM, Lee JY, Lee J, Kwok SK, Park SH. Atypical Femur Fracture in Rheumatoid Arthritis Patients Treated with Bisphosphonates: A Nested Case-Control Study [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/atypical-femur-fracture-in-rheumatoid-arthritis-patients-treated-with-bisphosphonates-a-nested-case-control-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/atypical-femur-fracture-in-rheumatoid-arthritis-patients-treated-with-bisphosphonates-a-nested-case-control-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology